Up Approx. 29%, Low Float (Nasdaq: NTRB) Could Start Popping Up On Radars Everywhere!

Are we watching a squeeze underway for (Nasdaq: NTRB)?

*Sponsored by Nutriband Inc. StockWireNews Up Approx. 29%, Low Float (Nasdaq: NTRB) Could Start Popping Up On Radars Everywhere! January 22nd Greetings Readers, Are we watching a squeeze underway for (Nasdaq: NTRB)? Since yesterday morning, NTRB has now pushed above 3 critical technical chart lines in its: 50-Day Simple Moving Average (SMA) 200-Day SMA 13-Day Exponential Moving Average Right now, with NTRB up approx. 29%, it could be on the hunt for more. And don't forget, when a low float of approximately 5.05Mn shares, a potential squeeze could happen quickly based on the volatility potential that comes along with floats of this size. Take a quick moment to review my initial (Nasdaq: NTRB) report below and consider getting it on your radar quickly. ----- It's a short week which means there's zero time to waste. Right now, I've got a report below on a past Nasdaq champ which I most recently profiled a couple years back. From that point? An approximate 175% mover. Popping approximately $6.00+ in under 12 months, this low float idea (just over 5Mn shares) could become an early breakout story in 2025. Why? Good question. Imagine a company at the forefront of innovation, pushing boundaries and redefining what's possible in their industry. With groundbreaking technology that could revolutionize patient care, this Biotech company is poised to make a significant impact on global health. As they prepare to unveil their flagship product, anticipation builds for a potential game-changer in the medical field. With a strong financial foundation and strategic partnerships in place, this under-the-radar Nasdaq profile is well-positioned to transform their visionary ideas into real-world solutions. That's why it may be time to consider this Nasdaq breakout idea for your watchlist: *Nutriband Inc. (Nasdaq: NTRB)* Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse-deterrent fent-a-nyl patch incorporating their AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on several potential breakout catalysts, NTRB has risen to the top spot on my watchlist: #1. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #2. Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! #3. Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. #4. Don't Look Past NTRB's Explosive Chart History As Multiple Surges Have Appeared Over The Past Year. But more on those in a second... Full Company Breakdown: Nutriband Inc. (Nasdaq: NTRB) Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Their model is to apply Transdermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. The company's first product and lead platform technology is AVERSA, an abuse deterrent tech which is applicable to any patch on the market today. According to Health Advances' assessment and upon approval by the United States FDA, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. The company has 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products.

Nutriband is earning revenues to keep their development burn at a minimum. They also own their own manufacturing and clinical development capabilities which drastically reduces their costs for AVERSA and other technologies. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes.

AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances' assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline

Sources: NTRB Website. NTRB Presentation. ----- As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now: #1. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily). According to info from the Yahoo Finance website, NTRB has a pretty low float. The website reports this profile to have roughly 5.05Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could positive company news early in 2025 provide a breakout spark? ----- #2. NTRB Potential Catalyst - Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fent-a-nyl in 2025 ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its fi-nan-cial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fent-a-nyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645k+ USD, up 50.94% YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS. Progress continues on the development of AVERSA Fent-a-nyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission. If approved, AVERSA Fent-a-nyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fent-a-nyl is estimated to have the potential to reach peak annual sales of $80-$200Mn, according to a market analysis report from Health Advances. AVERSA Buprenorphine, which is the company's second application for AVERSA, is projected to reach peak annual sales of up to $130Mn. ... Read the full article here. ----- #3. NTRB Potential Catalyst - Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. A handful of positive patent-related press releases have popped up in the last few months. Take a look: 12/27/24 - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology 11/27/24 - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology 10/31/24 - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application These developments strengthen NTRB's ability to defend and commercialize AVERSA™ globally, setting the stage for Nutriband to become the leader in abuse-deterrent technology. ----- #4. NTRB Potential Catalyst - Don't Look Past NTRB's Explosive Chart History As Multiple Surges Have Appeared Over The Past Year. Take a look at NTRB's 1-year chart:

Explosive. Explosive. Explosive. That's what NTRB has been over the past 12 month stretch. Here's a few surges of note: 3/26/24 - A low of $2.68 on March 26th became a high of $5.93 two days later. That's a run of 121%! 5/10/24 - Jumping from a low of $3.35 on the 10th to a high of $9.60 on July 24th, NTRB ran roughly 186%! 9/11/24 - From a low on the 11th of $3.75, NTRB erupted for 126% to a high of $8.49 on 10/10. Could another major move be right around the corner in 2025? ----- (Nasdaq: NTRB) Potential Catalyst Recap - The Top 4 To Consider Right Now #1. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #2. Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! #3. Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. #4. Don't Look Past NTRB's Explosive Chart History As Multiple Surges Have Appeared Over The Past Year. ----- Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). I'll be in touch with updates when necessary. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and StockWireNews ("SWN") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 1/21/25 and ending on 1/22/25 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, SWN Media LLC was paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid fifty-seven thousand five-hundred USD ("Funds"). Neither SWN Media LLC or its member own shares of (NTRB:US). Please see important disclosure information here: https://www.stockwirenews.com/disclosure/ntrb/ A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Nutriband Inc., TD Media LLC has been hired for a period beginning on 01/21/2025 and ending on 01/23/2025 to publicly disseminate information about (NTRB:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid two hundred and twenty-five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither TD Media LLC or its member own shares of (NTRB:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ntrb/ Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States

You deserve a chance to get in on the 2025 Uranium Boom

Join me for my #1 Uranium Play at 1:30 PM ET

With President Trump’s bullish stance on nuclear power, the 2025 Uranium Boom is upon us. And you deserve a chance to get in on it. At 1:30 PM ET today, I’ll show you further proof of why I believe we could be on the brink of the next leg up for this fuel source of nuclear power.   I’ll also reveal how billionaire investors stand to benefit BIG from The 2025 Uranium Boom and YOU could too… And reveal my #1 Uranium Play designed to make money in ANY market condition! I cannot promise future returns or against losses, but you owe it to yourself to see how good this Uranium BOOM could be and grab your seat for this free, LIVE event at 1:30 PM ET. See ya there, Geof

With President Trump’s bullish stance on nuclear power, the 2025 Uranium Boom is upon us.   And you deserve a chance to get in on it.   At 1:30 PM ET today, I’ll show you further proof of why I believe we could be on the brink of the next leg up for this fuel source of nuclear power.   I’ll also reveal how billionaire investors stand to benefit BIG from The 2025 Uranium Boom and YOU could too…   And reveal my #1 Uranium Play designed to make money in ANY market condition!   I cannot promise future returns or against losses, but you owe it to yourself to see how good this Uranium BOOM could be and grab your seat for this free, LIVE event at 1:30 PM ET.   See ya there,   Geof

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub

Morning Spotlight: Oncolytics Biotech Inc. (NASDAQ: ONCY) is Topping Our Watchlist Right Now

*Sponsored Just Announced! Oncolytics Biotech Inc. (NASDAQ: ONCY) is Our Next Potential Breakout Idea For Today… And Here’s Why… Targeting $116B Markets: Focused on oncology markets projected to surpass $116B by 2034, including breast, pancreatic, and stomach cancers. Analyst Coverage: HC Wainwright & Co. reaffirmed a $5 target for Oncolytics Biotech Inc. (NASDAQ: ONCY), which suggests a 525% potential upside. Major Collaborations: Partnerships with Roche, Pfizer, and leading academic institutions boost research and development efforts. 2025 Milestones: Key data releases and regulatory advancements planned across multiple cancer indications. Keep reading to see why we have all eyes on Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning… January 22, 2025 Dear Reader, It’s official! The countdown to the bell has begun. With only a few minutes to go, you need to see this… If you’re not paying attention to Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning, you could be missing out on one of the most exciting developments in oncology today.  Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t just part of the cancer treatment revolution—they’re leading it.  With groundbreaking research, industry-shaking collaborations, and a pipeline that’s redefining expectations, Oncolytics Biotech Inc. (NASDAQ: ONCY) is rewriting the rules and showing the world what innovation truly looks like. We have all eyes on Oncolytics Biotech Inc. (NASDAQ: ONCY) this morning as it takes the #1 position on our watchlist today.  In fact, a little over two months ago, on 11/14, Benzinga reported that HC Wainwright & Co., one of Wall Street’s oldest institutions, had reiterated a $5.00 target on Oncolytics Biotech Inc. (NASDAQ: ONCY).   This target suggests an upside potential of 525% from yesterday’s $.80 open. Now keep reading to see why we’re so excited about Oncolytics Biotech Inc. (NASDAQ: ONCY). Let’s start with the showstopper: the BRACELET-1 study.  This isn’t your average clinical trial. It’s a bold statement in the fight against HR+/HER2- metastatic breast cancer, proving that pelareorep, Oncolytics Biotech Inc. (NASDAQ: ONCY)’s groundbreaking immunotherapy is no ordinary treatment. Median Overall Survival (OS): Patients treated with pelareorep + paclitaxel achieved survival rates nearly double those on paclitaxel alone. Progression-Free Survival (PFS): The pelareorep combination extended PFS to 12.1 months compared to 6.4 months for paclitaxel monotherapy. Safety Profile: Remarkably strong, even in patients who had undergone extensive prior treatments. These results build on the earlier IND-213 study, further cementing pelareorep’s reputation as a game-changing therapy.  With the FDA already showing alignment on progression-free survival as a primary endpoint, Oncolytics is gearing up for a registration-enabling study targeting approximately 55K U.S. patients who urgently need better options. GOBLET Study: A Multi-Cancer Offensive Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t stopping at breast cancer.   Their GOBLET study is a full-scale attack on gastrointestinal cancers, tackling some of the toughest cases in oncology.  Conducted across 17 centers in Germany, this Phase 1/2 trial is exploring pelareorep’s potential in combination therapies for: 1st line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) 1st line MSI-high metastatic colorectal cancer 3rd line metastatic colorectal cancer 2nd line or later unresectable anal cancer Newly diagnosed metastatic PDAC The study’s design is as ambitious as its scope, and early results are turning heads. With Germany’s Paul-Ehrlich-Institute (PEI) giving the green light for Cohort 5 to move to full enrollment, Oncolytics is charging forward with confidence. Cohort 5: A Paradigm Shift in Pancreatic Cancer Pancreatic cancer is one of the most challenging diseases to treat, but Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t backing down.  Cohort 5 of the GOBLET study is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®).  Here’s what makes this trial so exciting: Positive Safety Review: The independent Data Safety Monitoring Board (DSMB) has already endorsed the safety profile, allowing the study to advance to full enrollment. Innovative Design: Blood and tumor samples are being collected for translational evaluations, ensuring a deeper understanding of pelareorep’s impact. Upcoming Data: Early safety results will debut at the 2025 ASCO GI Symposium, with efficacy results expected later in the year. “Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics Biotech Inc. (NASDAQ: ONCY). The results could mark a turning point in how this aggressive cancer is treated. Targeting Markets Worth Over $116B Oncolytics Biotech Inc. (NASDAQ: ONCY) is setting its sights on markets projected to exceed $116 bn within the next decade.  With its innovative approach and focus on transformative therapies, the company is strategically positioned to address some of the largest and fastest-growing segments in oncology: Global Breast Cancer Market: Reached $34.63B in 2024, growing to $38.06B in 2025, and predicted to surpass $89.01B by 2034. Global Stomach Cancer Treatment Market: Estimated at $6.08B in 2025 and expected to reach approximately $17.60B by 2034. Global Pancreatic Cancer Market: Accounted for $2.86B in 2024, increasing to $3.25B in 2025, and forecasted to hit $10.25B by 2034. By developing and advancing pelareorep, a groundbreaking immunotherapy, Oncolytics Biotech Inc. (NASDAQ: ONCY) is positioning itself to make a significant impact on these massive markets, meeting the unmet needs of patients worldwide. Partnering with Powerhouses Oncolytics Biotech Inc. (NASDAQ: ONCY) understands the value of teamwork, and they’ve partnered with some of the biggest names in the industry. The company is dedicated to advancing the development of pelareorep through partnerships with both industry and academic leaders. In the pharmaceutical world, Oncolytics Biotech Inc. (NASDAQ: ONCY) has teamed up with Roche Holding AG, Pfizer Inc., Merck Serono, Incyte Corporation, and Adlai Nortye to evaluate pelareorep in combination with therapeutic agents. On the academic front, Oncolytics has collaborated with the Mayo Clinic, Duke University, the Rutgers Cancer Institute of New Jersey, the Ohio State University Comprehensive Cancer Center, the Keck School of Medicine of the University of Southern California, PrECOG, SOLTI, and AIO-Studien-gGmbH to evaluate additional pelareorep-based combinations. Their collaboration with Roche on the GOBLET study brings unparalleled expertise to the table, while their alliance with the Global Coalition for Adaptive Research (GCAR) is a strategic masterstroke. GCAR’s innovative trial designs promise to accelerate timelines and reduce costs, giving Oncolytics a major competitive edge. 2025: The Year of Oncolytics Biotech Inc. (NASDAQ: ONCY) Here’s what Oncolytics Biotech Inc. (NASDAQ: ONCY) has on deck for 2025: H1 2025: Submit the GCAR-led adaptive registration-enabling trial protocol for first-line PDAC to the FDA. H1 2025: Present safety run-in data from GOBLET Cohort 5 at ASCO GI. H1 2025: Release updated efficacy data for GOBLET Cohort 4 in anal cancer. H2 2025: Share initial efficacy results from GOBLET Cohort 5. H2 2025: Enroll the first patient in the registration-enabling breast cancer study. Pelareorep And The Future of Immunotherapy Pelareorep isn’t just a treatment; it’s a revolution in the making. With its ability to convert “cold” tumors to “hot” ones, making them more susceptible to immune responses, this therapy is unlike anything we’ve seen before.  Its versatility across multiple cancer types and its proven efficacy make it a force to be reckoned with in the oncology world. Oncolytics Is Just Getting Started Oncolytics Biotech Inc. (NASDAQ: ONCY) isn’t here to play by the rules—they’re here to rewrite them. With trailblazing research, top-tier collaborations, and a relentless drive to innovate, they’re proving that cancer treatment doesn’t have to be business as usual.  Pelareorep is more than a therapy; it’s a beacon of hope, and its journey could be just the beginning.  7 Reasons Why We Have All Eyes On Oncolytics Biotech Inc. (NASDAQ: ONCY) This Morning… 1. Analyst Coverage: HC Wainwright & Co. recently reiterated a $5 target for Oncolytics Biotech Inc. (NASDAQ: ONCY), suggesting 525% in upside potential. 2. Targeting Markets Worth Over $116B : The company is focused on oncology markets projected to exceed $116B by 2034, including breast, pancreatic, and stomach cancers. 3. Breakthrough Results: The BRACELET-1 study demonstrated pelareorep nearly doubling overall survival (OS) and significantly extending progression-free survival (PFS) in HR+/HER2- metastatic breast cancer. 4. Bold Approach to Pancreatic Cancer: The GOBLET study's Cohort 5 has advanced to full enrollment with promising safety reviews, targeting one of the hardest-to-treat cancers. 5. Innovative Clinical Trial Strategies: Oncolytics Biotech Inc. (NASDAQ: ONCY) leverages GCAR’s cutting-edge trial designs to accelerate development timelines and reduce costs. 6. Collaborations with Industry Giants: Partnerships with Roche, Pfizer, and leading academic institutions strengthen Oncolytics Biotech Inc. (NASDAQ: ONCY)’s research and development capabilities. 7. A Packed 2025 Agenda: Oncolytics Biotech Inc. (NASDAQ: ONCY) plans key data releases and regulatory advancements, highlighting their progress across multiple cancer indications. Consider Taking a Look at Oncolytics Biotech Inc. (NASDAQ: ONCY) While It’s Still Early… With HC Wainwright & Co. backing a $5 target, breakthrough clinical results, and a focus on $116B worth of markets, Oncolytics Biotech Inc. (NASDAQ: ONCY) is grabbing attention where it counts.  With collaborations alongside industry titans like Roche and a packed 2025 agenda, we have all eyes on (ONCY) today.  Take a closer look while it’s still early—we’ll be covering (ONCY) today, so keep an eye out for my next update.  The morning spotlight is on (ONCY) right now. I’ll check back with you shortly! Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/ *Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 01/21/2025 and ending on 01/22/2025 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, we have been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (ONCY:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/oncy/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice